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Abstract
Reliable procedures are needed to quantify the performance of instruments and methods in order to increase the quality in clinical laboratories. The 
Sigma metrics serves that purpose, and in the present study, the current methods for the calculation of the Sigma metrics are critically evaluated. 
Although the conventional model based on permissible (or allowable) total error is widely used, it has been shown to be flawed. An alternative 
method is proposed based on the within-subject biological variation. This model is conceptually similar to the model used in industry to quantify 
measurement performance, based on the concept of the number of distinct categories and consistent with the Six Sigma methodology. The quality 
of data produced in clinical laboratories is expected, however, to be higher than the quality of industrial products.
It is concluded that this model is consistent with Six Sigma theory, original Sigma metrics equation and with the nature of patients’ samples. There-
fore, it can be used easily to calculate the performance of measurement methods and instruments used in clinical laboratories.
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Introduction
The Six Sigma model is accepted as the latest ver-
sion of total quality management (TQM) and is 
widely implemented in industry, business and 
healthcare sector. It is regarded as a powerful 
management tool and provides specific methods 
that have the potential to significantly reduce the 
error rate (1). Six Sigma methodology is data-driv-
en and uses a specific problem-solving approach 
largely based on statistical procedures (2). In the 
Six Sigma model, the Sigma metrics (SM) is the 
central objective quality measure and the basis for 
quality control development (3,4). 
According to the Six Sigma theory the perfor-
mance of a process can be measured easily using 




2 x Process SD
 =
The process tolerance is calculated as the differ-
ence (or interval) between the upper and lower 
tolerance limits (UL and LL, respectively); and SD 
represents standard deviation. 
The Six Sigma methodology was later transferred 
to laboratory medicine and SM of the measuring 






where pTE is the total permissible (or allowable, 
TEa) error and is calculated as shown in Eq. 3, 
(Eq. 1)
(Eq. 2)
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where k1 is the coverage factor (1.65 for 90% prob-
ability) and CVA the analytical coefficient of varia-
tion (5).
pTE = Bias + k1 x CVA (or SD)
Maximum permissible bias and CVA can be drawn 
from the data of biological variation as shown be-
low (Eq. 4 and 5),
Bias =  k2 x    CVI + CVG 
2 2
CV  =  k3 x  CVI  
where CVI is the within subject biological varia-
tion, CVG the between subject biological variation, 
and k2 and k3 are coverage factors. In these equa-
tions the coverage factors (kn) are variables that 
depend on the test types and quality require-
ments.
As shown in Eq. 2, in laboratory medicine the SM is 
not calculated using the original equation of Six 
Sigma methodology (Eq. 1), but using a modified 
equation (Eq. 2). Equation 2 is based on the total 
error model, where pTE is derived from the esti-
mates of the CVI and CVG (Eq. 3, 4 and 5) using kn 
coverage factors. The calculation of pTE has, how-
ever, been criticized for several reasons, e.g. be-
cause of the flawed method combining mutually 
exclusive factors of bias and imprecision (6,7). Fur-
thermore, the (pTE – Bias) term does not reflect 
the tolerance limit (TL) concept used in industry. 
The calculation of the SM according to the conven-
tional model seems straightforward, but on closer 
observation there are some serious complications 
rendering the estimation questionable. 
According to the Six Sigma model and Eq. 1, the 
calculation of the SM requires a TL and not a maxi-
mum variation as a limit. With a reliable TL, it is 
easy to derive analytical performance specifica-
tions and also the SM. In the present study, the 
conventional method to derive a TL from the ex-
pression (pTE – Bias) is questioned and an alterna-
tive model based on within-subject biological and 
analytical variations to calculate SM objectively in 
laboratory medicine is presented. To understand 
the defects of the model used in laboratory medi-
cine, first of all, we should examine the compo-
nents of nominator of Eq. 1 and 2. 
Tolerance limit
Tolerance can be defined as the amount of errors 
or defects that can be tolerated by the customer 
or user for a given product. The tolerance limit is 
determined by the customers or users and not by 
the manufacturer or production system. There-
fore, we calculate the performance of a system us-
ing the TL determined by the customers/users and 
deviations obtained from the products. Similarly, 
in laboratory medicine we should calculate the 
performance of the instruments/methods using 
the TL given by the physicians or patients and de-
viations obtained from the test results (Figure 1). 
The equation of the performance used in Six Sig-
ma theory has three components: TL which is de-
termined by customers/users, deviation which is 
obtained from the products and SM which is the 
indicator of the quality of the production system. 
Consequently, the TL should not be determined 
by the production system or products itself. 
In laboratory medicine we use (pTE – Bias) as the TL; 
however (pTE – Bias) is linked to the instruments 
and methods. As shown in Eq. 3, 4 and 5, pTE is de-
rived from bias and CVA using coverage factors (kn) 
which is (partly) related to the test types and meth-
ods. Both k2 and k3 depend on the performance of 
the methods or the number of test results accepted 
to be defects. When we use quality specifications 
based on biological variation, k factors become the 
link between method performance and biological 
variation. Therefore, in the (pTE – Bias) model, the 
TL is (in part) a property of the method/instrument 
and this is a clear contradiction with the Six Sigma 
concept. Additionally, according to the ‘Internation-
al vocabulary of metrology’ (VIM 3; 4.26) the term 
“tolerance” should not be used to designate ‘maxi-
mum permissible error’ (8).
Bias as a component of tolerance limit
The second defect of the conventional model is 
the inclusion of the additional bias in the model 
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In the model used in industry, there is no bias in 
the nominator of the SM equation (Eq. 1). This does 
not mean that the bias is not present or neglected 
in the process. Principally, if the bias is present we 
should correct it. However, in a given time we do 
not know whether the bias is present or not. 
Therefore, in the industrial model the presence of 
1.5 SD shift is accepted in advance. Nevertheless, 
for simplicity this shift is not included in the SM 
equation. Instead, it is included in the conversion 
table of SM/defects per million opportunities 
(DPMO). When we convert SM to DPMO we use 
the table prepared according to short SM-1.5SD. 
Alternatively, if we measure bias but are unable to 
correct it, we can calculate SM using z transforma-
tion model based on the actual number of results 
outside the LL and UL (9). On the other hand, in 
the model used in laboratory medicine, in addi-
tion to 1.5 SD shift, the measured bias is also in-
cluded (in fact we need to correct and eliminate it) 
in the nominator of SM equation, as TEa – Bias. As 
a result, the SM of conventional model has two bi-
ases: the measured bias of the process and 1.5 SD 
shift. Certainly, in this situation, depending on the 
measured bias value, the calculated performance 
of the process will be lower (even extremely lower) 
than the actual performance (9).  
Conventional calculation of Sigma metrics in 
laboratory medicine
As we mentioned previously, in the Six Sigma 
model we define upper and lower tolerance limits 
based on the required product performance. In 
the example (Figure 2), assume a process with vari-
ation (σ) of 1, mean of 0, and TL at ± 2.5 SD:
The observations outside the UL and LL are the 
defects, counted as DPMO. Outside the 2.5 SD lim-
it will be 0.62% of the observations in case of an 
assumed Gaussian distribution; for one side DPMO 
is 6200. According to the Six Sigma reasoning, the 
quality goal is to improve the production process, 
bringing down the variance to a level of TLs at 6 
SD, not at 2.5 SD as in the example. 
Figure 1. Sigma metrics calculation models used in industry and laboratory medicine. p(TE) – permissible total error.
Figure 2. Example of a conventional Six Sigma model with tol-
erance limits at ± 2.5 standard deviations. μ – mean. σ – varia-
tion.
The model of Sigma metrics calculation
used in industry and business
The model of Sigma metrics calculation






Variation is calculated from the Variation is calculated from the
Tolerance limits are determined by
Sigma metrics is calculated by using tolerance
limit determined by customers/users and
variation of products
Sigma metrics is calculated from p(TE)
and variation of test results
p(TE) is determined by using the maximum
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In laboratory medicine, analytical performance 
specifications are in most cases not directly ex-
pressed as a TL, but are expressed as maximum 
CVA (Eq. 6) (5).
CVA < 0.5 CVI 
Generally, the CVI is used to define the perfor-
mance specification, as this is most applicable 
when a test is used for monitoring.
Starting with a maximum CVA, how to derive the 
TLs as required in the Six Sigma model for calcula-
tion of the SM? By substituting SD for CVA, the TL 
in the conventional model is defined as TEa or pTE.
From the Eq. 1, 2 and 3, the TL used in laboratory 
medicine can be simplified as given in Eq. 7.
TL = p(TE) – Bias = Biasmax + 1.65SDmax – Bias
The maximum acceptable bias (Biasmax) and CVA 
(or SD) can be taken at desirable level (minimum 
or optimum level depending on test performance) 
and in this case, Eq. 6 and 7 can be combined and 
simplified as given below (Eq. 8),
TL = p(TE) – Biasd = Biasd + 1.65SDd – Biasd =
1.65 x (0.5 SDi )  
where d is the desirable level of analytical specifi-
cation and SDI the within subject SD. A coverage 
factor of 1.65 is introduced. With this limit, it is ac-
cepted that a maximum of 5% of the results will be 
outside the LL and UL (Figure 3).
What is the SM of the maximum permissible ana-
lytical variation? According to the conventional 
theory (Eq. 9), with an analytical SD (SDA) of 0.5 
SDI, the SM = 1.65 (10).
Note the circular reasoning here, as the limit is de-
fined by a percentage of results outside the limit 
(5%), which defines a sigma score. In other words, 
in Eq. 9, based on pTE, both nominator and de-
nominator contain the same term 0.5 SDI, render-
ing a result always equal to the coverage factor (in 
case of SDA = 0.5 SDI). Therefore, the SM calculated 
by Eq. 9, is determined by the coverage factor and 
cannot predict the performance of measurement 
methods. As an illustration of this circular reason-
ing, let us assume another coverage factor, with 
another percentage outside this limit, e.g. pTE = 
3.0 (0.5 SDI). With a coverage factor of 3.0 it is ac-
cepted that only 0.13% of the results will be out-
side the tolerance limit. What is the SM of this per-
formance? According to the conventional theory, 
 3.0 x (0.5 x SDI)
SDA
SM = , with a SDA = 0.5 SDI, the
SM = 3.0. Note that we have a higher sigma score 
with unchanged quality specifications: the maxi-
mum SDA still is equal to 0.5 SDI. The reason for 
this equality is, that accepting 5% of results out-
side the tolerance limit at 1.65 SD is equivalent to 
accepting 0.13% outside 3.0 SD. This shows that 
the choice of sigma limit is arbitrary and results in 
circular reasoning. In the Six Sigma model the pro-
cess design should result in a minimum number of 
defects outside the performance limits as possi-
ble, preferable < 4 per million defining Six Sigma 
quality. However, here a TL is defined that at the 
same time accepts as much as 5% “defects”. This 
seems to contradict the Six Sigma principle. 
This leaves the question unanswered how to de-
fine the TLs in laboratory medicine based on a 
maximum SDA of 0.5 SDI. 
Another approach to this problem might be the 
internal quality control (IQC) design needed for 
the different TLs. Obviously, the conventional SM 
of 1.65 is too low to maintain with quality control, 
as a SM of at least 3.0 would be needed. If the 
measurement method performs just within the 





Figure 3. Conventional Six Sigma model in laboratory medicine 
with tolerance limits at ± 1.65 SD. μ – mean. σ – variation.
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nal quality control was set at 1.65 SD, 5% of the re-
sults would be rejected (or 10% two-sided). This 
would obviously be too impractical for routine 
use. Therefore, a lower SDA is needed to maintain 
the pre-defined performance. 
Let us assume a SDA that is lower, so the perfor-
mance could properly be maintained with quality 
control procedures. In that case, 4.65 SDA should 
fit within the tolerance limit instead of 1.65.
According to the conventional TEa/Six Sigma 
model, assuming that the TL (pTE) is at 1.65 (0.5 
SDI) or 1.65 SDmax, and we assume 4.65 SDA within 
this limit, we should have an analytical SDA of 0.35 
SDmax to properly maintain the required quality. 
With an IQC limit at 3.0 SDA (equal to 1.1 SDmax) we 
still have the required 1.65 SDA safely margin. In 
case of a shift (bias) of 1.65 SDA we have an error 
detection of 9% (singular measurement) and only 
an expected 0.13% of the results outside the TL. In 
case of a larger shift of 3.0 SDA we have an error 
detection of 50%, with 5% of results outside the 
TL. This 5% outside the 1.65 SDA limit is equal to 
the 5% outside this limit of the 0.5 SDI curve (Fig-
ure 4). The question is what is the SM of this sys-
tem? According to the conventional model, 
 1.65 x (0.5 x SDI)
SDA
SM = , with SDa = 0.355 (0.5 SDI)
the SM = 4.65.
Alternatively, we could choose an IQC model with 
a TL at 3.0 SD corresponding to 0.13% of results 
outside the limit, instead of 1.65 SD with 5% out-
side the limit (Figure 5). Assuming that the TL is at 
3.0 SDmax and we again assume 4.65 SDA within 
this limit, we should have an analytical SDA of 0.65 
SDmax to properly maintain the required quality. 
With an IQC limit at 3.0 SDA (1.94 SDmax) there still 
is a 1.65 SDA safely margin. In case of a shift (bias) 
of 1.65 SDA, the error detection is again 9% and ex-
pected 0.13% of the results outside the TL. In case 
of a larger shift of 3.0 SDA (1.94 SDmax) we have an 
error detection of 50%, with 5% of results outside 
the limit. 
The SM of this system is  3.0 x (0.5 x SDI)
SDA
SM = , 
and with SDA = 0.645 (0.5 SDI) = 0.323 SDI, the SM 
= 4.65
Both the TL and SDA were increased in proportion, 
resulting in an unchanged SM of 4.65. The prob-
lem how to define the TL has now been shifted to 
the problem how to maintain the required SDmax 
by IQC. Note that a coverage factor of 3.0 is gener-
ally accepted when maintaining a certain analyti-
cal variation, so the first coverage factor of 1.65 
could be regarded as too strict (11). 
Measurement theory in industry
The Six Sigma concept originates from industry, 
first introduced by Motorola in 1986. Methods for 
quality control of manufacturing processes have 
Figure 4. Example of a maximum analytical standard devia-
tion (SDmax) equal to 0.5 within subject standard deviation (SDI); 
SD as ratio with SDmax the actual SDA needed to maintain this 
performance with quality control procedures is much smaller: 
SDA = 0.355 SDmax. μ – mean. σ – variation. IQC – internal quality 
control. 
Figure 5. Maximum analytical standard deviation (SDmax) is 
equal to 0.5 within subject standard deviation (SDI), with IQC 
limit at 1.94 SDmax and tolerance limit at 3.0 SDmax. X-axis: SD as 
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many concepts in common with those in labora-
tory medicine. In industry, products should fulfil 
the pre-set quality specifications and measure-
ment procedures should be of sufficient accuracy 
and precision to distinguish good from bad prod-
ucts. The methods of measurement procedures of 
the Automotive Industry Action Group (AIAG) are 
often referred to when the specifications of meas-
urement system analysis in industry are described 
(12). In automobile industry, the quality require-
ments are high: a component with a quality below 
limits could lead to substantial financial loss. Al-
though the Six Sigma model is broadly applied in 
production processes, it should be noted that in 
contrast to laboratory medicine, the quality of 
measurement according to the AIAG is not ex-
pressed as SM but as ‘Number of Distinct Catego-
ries’ (NDC). 
The criteria as to whether a measurement system’s 
variability is satisfactory depends upon the manu-
facturing production process variability in relation 
to the measurement system variability. The NDC 
refers to the number of distinct (non-overlapping) 
categories that can be distinguished by a measur-
ing system in relation to the variability of the prod-
uct to be measured. Following this procedure, the 
ratio of the process (or part) variability to the varia-
tion of the measurement system (named repeata-
bility and reproducibility) is calculated (Eq. 10). 
σpart
σmeasurement
NDC =     2
See Table 1 for a common interpretation of these 
ratios. Central here is the concept of NDC (AIAG).
Alternative Sigma metrics calculation in 
laboratory medicine
We propose a model to calculate the SM that is 
consistent with both Six Sigma model and the 
quality principles in laboratory medicine. As 
shown above the main discrepancies between the 
model used in industry and laboratory medicine is 
the TL. We need a reliable TL which is consistent 
with both Six Sigma theory and laboratory facts. 
The new model is illustrated in Figure 6 and Table 2.
In the new model, we thought that the TL of ana-
lytes being measured in clinical laboratories 
should be consistent with the hierarchy of models 
of Milan consensus as given below: 
•	 Model 1. The effect of analytical performance 
on clinical outcomes;
•	 Model 2. The biological variation of the meas-
urand;
•	 Model 3. State-of-the-art analytical perfor-
mance of the measurement (13). 
Decision interval and/or within subject biological 
variation can be accepted as the TL. This approach 
is consistent with the Six Sigma theory. Although 
Model 1 is the preferred model, it has limited appli-
cation since this needs a well-defined decision limit. 
On the other hand, the biological variation of the 




to be an acceptable 
measurement system
Recommended, especially useful when trying to sort or classify parts or when tightened 
process control is required.
4 - 14 May be acceptable for some applications
Decision should be based upon, for example, importance of application measurement, 
cost of measurement device, cost of rework or repair. Should be approved by customer.
< 4 Considered to be unacceptable
Every effort should be made to improve the measurement system. This condition may 
be addressed by the use of an appropriate measurement strategy; for example, using the 
average results of several readings of the same part characteristic in order to reduce final 
measurement variation.
NDC - the number of distinct categories that can be distinguished by a measuring system in relation to the variability of the 
product to be measured.
Table 1. Decision-making based on the number of distinct categories used in automotive industry
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most cases. Within subject biological variation is 
the inherent variation of the measurand and direct-
ly related to patients’ metabolism and not to the 
methods and/or instruments of the laboratory. 
Therefore, it can be used as the TL of the measurand.
In the proposed model, the SM of the process is 
estimated as a ratio of CVI of the measurands to 
the measurement (analytical) variation (CVA). Prin-
cipally it is similar to SM calculation in industry and 
the model of NDC. In this model, we do not use a 
coverage factor such as 1.65. 









SM =  = 4.65, and CVA = 0.22 CVI.
Figure 6. The current and proposed model to calculate sigma metric in laboratory medicine. p(TE) – permissible total error.
Test CVA* (%) CVI (%) CVG (%) pTE† (%) SMpTE SMBV NDC
Creatinine 2.6 5.9 14.7 8.9 3.5 2.3 3.3
Sodium 1.1 0.6 0.7 0.7 0.7 0.54 0.8
Potassium 1.4 4.6 5.6 5.6 4.1 3.38 4.9
Glucose 0.7 5.6 7.5 7.0 9.9 8.0 11.3
Iron 1.8 26.5 23.2 30.7 17.3 15.0 21.2
Albumin 2.6 3.2 4.75 4.07 1.6 1.2 1.7
TSH 1.2 19.3 24.6 38.2 30.6 15.4 21.8
CVA - analytical variation. CVI – within-subject biological variation. CVG – between-subject biological variation. SMpTE – Sigma 
metrics (SM) derived from permissible total error (pTE). SMBV - Sigma metrics derived from (within-subject) biological variation (CVI). 
*Values obtained from local laboratory as example. †Conventional TE model SMpTE: [0.25 (CVI2 + CVG2)0.5 + 1.65 (0.5 CVI)] / CVA (14). 
Alternative model, SMBV = CVI / CVA. NDC – number of distinct categories; 1.41 (CVI / CVA); note that the limit is 4, while a minimum 
SM is generally considered to be 3.
Table 2. Calculation of Sigma metrics according to different models compared to the number of distinct categories 
(Eq. 11)
Current model Proposed model
Physicians/PatientsPhysicians/Patient
Laboratory Instruments/Methods
Test results Test results 
Variation is calculated from the Variation is calculated from the
Sigma metrics is calculated from within subject
 biological variation and variation of test results
Laboratory Instruments/Methods
Sigma metrics is calculated from p(TE)
and variation of test results
p(TE) is determined by using the maximum
acceptable bias and analytical variation of the
Tolerance limits are determined by
as "decision interval" or "within subject
biological variation"
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Discussion
We have shown that it is complicated to derive a 
reliable SM based on a maximum analytical varia-
tion according to the common definition CVA < 0.5 
CVI. In our opinion, the conventional definition of 
the SM based on pTE is flawed due to circular rea-
soning, and is arbitrary to a high degree.  
The main problem of SM calculation in laboratory 
medicine is the lack of a reliable method for the 
estimation of TLs. These are essential not only for 
SM but also for quality specifications and develop-
ment of IQC methods. Therefore, various attempts 
have been made to find a solution for a consistent 
procedure specific to laboratory medicine such as 
Milan and Stockholm consensus (13,15). 
We proposed that the CVI of measurands could be 
accepted as the TL of the measurands due to the 
following reasons: 
1. Biological variation originates from patients 
and reflects the natural variation of measur-
ands; 
2. Biological variation data are not method and/or 
instrument dependent; 
3. It is consistent with Six Sigma theory and SM 
equation (Eq. 1 to 11);
4. It has no coverage factor such as pTE and not 
influenced by the bias as the current model 
used in laboratory medicine; 
5. It is test specific and does not vary among labo-
ratories. Therefore, it could be preferred as the 
reference for harmonization of the measure-
ment of instruments/methods performance. 
The presented model, in a way is also similar to the 
NDC concept that is being used in automotive in-
dustry. The advantage of NDC model is that no TL 
is needed and this model is not prone to errors 
such as the conventional model based on pTE. Ad-
ditionally, in this model we do not use various cov-
erage factors such as 1.65 or 3 to exclude a given 
percentage of data, which makes TL defective.
If we define a maximum permissible analytical var-
iation based on the CVI, it should be noted that 
there is a corresponding analytical variation that is 
more strict and will serve as the actual maximum 
analytical variation applied in IQC and that will in-
clude a safety margin in order to maintain the 
maximum permissible variation with a predefined 
probability. According to the proposed model, the 
ratio SDA / SDI (or CVA / CVI) would be 0.22 for the 
required 4.65 Sigma metric. 
In classical Six Sigma theory, despite the pre-ac-
ceptance of 1.5 SD shift (as in “long term” SM), the 
defect rate is less than 4 DPMO. It should be noted 
that Six Sigma originated from industry and not 
from the healthcare sector. Currently, the expect-
ed quality level required in automotive or aviation 
sectors are higher than even 6 sigma. However, we 
cannot assume that the desired quality level in 
laboratory medicine is lower than in the automo-
tive or aviation sectors. The 3 sigma quality level, 
that is the accepted minimum quality for labora-
tory medicine, is far away from the quality of in-
dustrial products. To decrease laboratory errors to 
a negligible level we should investigate new and 
sound models to evaluate the performance of 
measurement methods objectively. 
The proposed model does not take bias into ac-
count. This is not a defect of the model. Remem-
ber that in the Six Sigma theory (Eq. 1) we also do 
not include bias directly to the equation of SM, be-
cause we use the SM/DPMO conversion table pre-
pared according to the short SM - 1.5 SD. Addition-
ally, it has been stated that many forms of short-
time bias are being included in the intermediate 
analytical imprecision and can be regarded as un-
correctable (7). It can be argued that other forms 
of bias that are correctable (e.g. due to bias in 
standards higher in the traceability chain) should 
not be expressed in the SM as quality measure on 
the level of the individual laboratory.   
Although consensus has been reached to accept 
the biological variation as basis for calculation of 
performance specifications, two major issues of 
biological variation must be addressed. Firstly, the 
published biological variation data vary signifi-
cantly and may not always be reliable; and sec-
ondly, data of biological variation are not available 
for all measurands. Recently the European Federa-
tion of Clinical Chemistry and Laboratory Medi-
cine (EFLM) Biological Variation Working Group in-
itiated the European Biological Variation Study 
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(EuBIVAS) and collected samples from six Europe-
an countries following a stringent protocol (16). So 
far, biological variation estimates for several meas-
urands have been determined and others are in 
preparation (17-19). An update of the biological 
variation database has been planned and will be 
made available.  
In conclusion, this study shows that the conven-
tional method for calculation of the SM is flawed. 
An alternative method for calculation of the SM, 
which is consistent with both Six Sigma theory, 
and concept of performance specifications based 
on biological variation is presented. This new 
method is simple and can be used by laboratory 
staff easily.
Potential conflict of interest
None declared.
References
1. Harry M, Schroeder R. Six Sigma, the breakthrough ma-
nagement strategy revolutionizing the world’s top corpora-
tions. New York:Currency;2005. 
2. Brussee W. Statistics for Six Sigma made easy. New 
York:McGraw-Hill;2004.
3. Coskun A, Oosterhuis WP, Serteser M, Unsal I. Sigma metric 
or defects per million opportunities (DPMO): the performan-
ce of clinical laboratories should be evaluated by the Sigma 
metrics at decimal level with DPMOs. Clin Chem Lab Med 
2016;54:e217-9. https://doi.org/10.1515/cclm-2015-1219
4. Hens K, Berth M, Armbruster D, Westgard S. Sigma metrics 
used to assess analytical quality of clinical chemistry assays: 
importance of the allowable total error (TEa) target. Clin 
Chem Lab Med 2014;52:973-80. https://doi.org/10.1515/
cclm-2013-1090
5. Fraser CG. Biological variation: from principles to practice. 
Washington:AACC Press;2001.
6. Oosterhuis WP. Gross overestimation of total allowable error 
based on biological variation. Clin Chem 2011;57:1334-6. 
https://doi.org/10.1373/clinchem.2011.165308
7. Oosterhuis WP, Bayat H, Armbruster D, Coskun A, Freeman 
KP, Kallner A, et al. The use of error and uncertainty methods 
in the medical laboratory. Clin Chem Lab Med 2018;56:209-
219. https://doi.org/10.1515/cclm-2017-0341
8. BIPM, IEC, IFCC, ILAC, IUPAC, IUPAP, ISO, OIML. The internati-
onal vocabulary of metrology—basic and general concepts 
and associated terms (VIM), 3rd ed. JCGM 200:2012.
9. Coskun A, Serteser M, Kilercik M, Aksungar F, Unsal I. A new 
approach to calculating the Sigma Metric in clinical labo-
ratories. Accred Qual Assur 2015;20:147-152. https://doi.
org/10.1007/s00769-015-1113-8
10. Westgard JO. Six Sigma Quality Design and Control: Desira-
ble Precision and Requisite QC for Laboratory Measurement 
Processes. Madison:Westgard QC, Inc.; 2001.
11. German Medical Association on Quality Assurance in Me-
dical Laboratory Examinations (Rili-BAEK). Revision of the 
“Guideline of the German Medical Association on Quality 
Assurance in Medical laboratory Examinations – Rili-BAEK” 
(unauthorized translation). Lab Med 2015;39:26–69.
12. Automotive Industry Action Group (Chrysler Group LLC, 
Ford Motor Company, General Motors Corporation, AIAG). 
Measurement Systems Analysis Reference Manual, 4th ed. 
Detroit:AIAG;2010.
13. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oo-
sterhuis W, et al. Defining analytical performance specifica-
tions: Consensus Statement from the 1st Strategic Confe-
rence of the European Federation of Clinical Chemistry and 
Laboratory Medicine. Clin Chem Lab Med 2015;53:833-5. 
https://doi.org/10.1515/cclm-2015-0067
14. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Ji-
menez CV, et al. Desirable specifications for total error, im-
precision, and bias, derived from intra- and inter-individual 
biologic variation. Available at: http://www.westgard.com/
biodatabase1.htm. Accessed February 5th, 2018.
15. Hyltoft Petersen P, Fraser CG, Kallner A, Kenny D. Strategies 
to set global analytical quality specifications in laboratory 
medicine. Scand J Clin Lab Invest 1999;59:475–585.
16. Carobene A, Strollo M, Jonker N, Barla G, Bartlett WA, 
Sandberg S, et al. Biological Variation Working Group, Euro-
pean Federation of Clinical Chemistry and Laboratory Me-
dicine. Sample collections from healthy volunteers for biolo-
gical variation estimates’ update: a new project undertaken 
by the Working Group on Biological Variation established 
by the European Federation of Clinical Chemistry and La-
boratory Medicine. Clin Chem Lab Med 2016;54:1599-608. 
https://doi.org/10.1515/cclm-2016-0035
17. Carobene A, Marino I, Coskun A, Serteser M, Unsal I, Gu-
erra E, et al. The EuBIVAS project: Within- and between-su-
bject biological variation data for serum creatinine using 
enzymatic and alkaline picrate methods and implications 
for monitoring. Clin Chem 2017;63:1527-36. https://doi.
org/10.1373/clinchem.2017.275115
18. Carobene A, Røraas T, Sølvik UØ, Sylte MS, Sandberg S, Gu-
erra E, et al; European Biological Variation Study of the 
EFLM Working Group on Biological Variation. Biological Va-
riation Estimates Obtained from 91 Healthy Study Partici-
pants for 9 Enzymes in Serum. Clin Chem 2017;63:1141-50. 
https://doi.org/10.1373/clinchem.2016.269811
19. Coşkuna A, Carobene A, Kilercik M, Serteser M, Sandberg S, 
Aasne K, et al.; European Biological Variation Study of the 
EFLM Working Group on Biological Variation. Within-su-
bject and between-subject biological variation estimates 
of 21 hematological parameters in 30 healthy subject. Clin 
Chem Lab Med 2018 Apr 2 [cited 2018 Feb 5]. [Epub ahead 
of print]. https://doi.org/10.1515/cclm-2017-1155
